CN114929707A - Eed抑制剂及其制备方法和用途 - Google Patents

Eed抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN114929707A
CN114929707A CN202080079623.6A CN202080079623A CN114929707A CN 114929707 A CN114929707 A CN 114929707A CN 202080079623 A CN202080079623 A CN 202080079623A CN 114929707 A CN114929707 A CN 114929707A
Authority
CN
China
Prior art keywords
haloalkyl
alkyl
group
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080079623.6A
Other languages
English (en)
Other versions
CN114929707B (zh
Inventor
戚炜
张海珍
马欣
雷晖
张玉华
曲玉秀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hejing Pharmaceutical Technology Shanghai Co ltd
ShanghaiTech University
Original Assignee
ShanghaiTech University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ShanghaiTech University filed Critical ShanghaiTech University
Publication of CN114929707A publication Critical patent/CN114929707A/zh
Application granted granted Critical
Publication of CN114929707B publication Critical patent/CN114929707B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

涉及式(X)化合物，或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂合物，以及含有所述化合物的药物组合物和用途。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN202080079623.6A 2019-11-01 2020-11-02 Eed抑制剂及其制备方法和用途 Active CN114929707B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019110590722 2019-11-01
CN201911059072 2019-11-01
PCT/CN2020/125873 WO2021083380A1 (zh) 2019-11-01 2020-11-02 Eed抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN114929707A true CN114929707A (zh) 2022-08-19
CN114929707B CN114929707B (zh) 2024-04-09

Family

ID=75715884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079623.6A Active CN114929707B (zh) 2019-11-01 2020-11-02 Eed抑制剂及其制备方法和用途

Country Status (8)

Country Link
US (1) US20230028221A1 (zh)
EP (1) EP4056570A4 (zh)
JP (1) JP7481689B2 (zh)
KR (1) KR20220097449A (zh)
CN (1) CN114929707B (zh)
AU (1) AU2020374041B2 (zh)
CA (1) CA3156546A1 (zh)
WO (1) WO2021083380A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368368A (zh) * 2022-08-24 2022-11-22 郑州大学 一种8-吲哚[4,3-c]嘧啶并[1,2,4]三氮唑类衍生物及制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103155A1 (en) * 2014-12-23 2016-06-30 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2017219948A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019158025A1 (zh) * 2018-02-13 2019-08-22 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016103155A1 (en) * 2014-12-23 2016-06-30 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2017219948A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019158025A1 (zh) * 2018-02-13 2019-08-22 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
US20230028221A1 (en) 2023-01-26
CA3156546A1 (en) 2021-05-06
AU2020374041A1 (en) 2022-06-09
KR20220097449A (ko) 2022-07-07
EP4056570A4 (en) 2023-12-20
CN114929707B (zh) 2024-04-09
JP2023502889A (ja) 2023-01-26
JP7481689B2 (ja) 2024-05-13
EP4056570A1 (en) 2022-09-14
AU2020374041B2 (en) 2024-02-08
WO2021083380A1 (zh) 2021-05-06

Similar Documents

Publication Publication Date Title
EP4092026A1 (en) Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof
CN113651814A (zh) Kras突变蛋白抑制剂
CN110386944B (zh) 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
CN109851638B (zh) 取代的二氨基嘧啶化合物
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
CN103582638A (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN116478136A (zh) 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂
TW202110831A (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
WO2022188709A1 (zh) 噻吩类化合物及其应用
ES2877686T3 (es) Agonista S1P1 y aplicación del mismo
WO2021083380A1 (zh) Eed抑制剂及其制备方法和用途
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
CN112574208B (zh) 取代的稠合三环衍生物及其组合物及用途
US11236086B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
JP2021522165A (ja) ２，６−ジアミノ−３，４−ジヒドロピリミジン−４−オン誘導体および治療におけるその使用
TWI810547B (zh) Pd-l1拮抗劑化合物
CN115594682B (zh) Fgfr2抑制剂
CN114874189B (zh) 取代的杂芳基衍生物及其组合物及用途
WO2023086575A1 (en) Btk inhibitors
EP3885346A1 (en) Aminopyrimidine compound used for inhibiting activity of protein kinase
KR20230083276A (ko) 오토탁신 억제제 화합물
CN113336760A (zh) 取代的酰胺衍生物及其组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230410

Address after: No. 393, Huaxia Middle Road, Pudong New Area, Shanghai, 201210

Applicant after: SHANGHAITECH University

Applicant after: Hejing Pharmaceutical Technology (Shanghai) Co.,Ltd.

Address before: No. 393, Huaxia Middle Road, Pudong New Area, Shanghai, 201210

Applicant before: SHANGHAITECH University

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant